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Familial phenotype differences in PKD1. Extrarenal manifestations can be divided into cystic and
Background. Mutations within the PKD1 gene are responsi- noncystic, with cysts occurring in liver, ovary, pancreas,
ble for the most common and most severe form of autosomal spleen, and central nervous system [2]. Common compli-dominant polycystic kidney disease (ADPKD). Although it is
cations arising from the disorder include hypertension,known that there is a wide range of disease severity within
macrohematuria, urinary tract infection, abdominal andPKD1 families, it is uncertain whether differences in clinical
severity also occur among PKD1 families. back pain, cardiac valve abnormalities, hernia, and sub-
Methods. Ten large South Wales ADPKD families with at arachnoid hemorrhage from intracranial aneurysms.
least 12 affected members were included in the study. From There is marked variability of clinical expression inaffected members, clinical information was obtained, including
ADPKD, which is explained, in part, by genetic hetero-survival data and the presence of ADPKD-associated compli-
geneity. The condition is caused by mutations in at leastcations. Family members who were at risk of having inherited
ADPKD but were proven to be non-affected were included three different genes: PKD1 on chromosome 16p13.3
as controls. Linkage and haplotype analysis were performed [3], PKD2 on 4q21-23 [4], and a third, thus far unidenti-
with highly polymorphic microsatellite markers closely linked
fied gene [5–7]. PKD1 is responsible for ADPKD into the PKD1 gene. Survival data were analyzed by the Kaplan–
approximately 85% of European families [8] and is asso-Meier method and the log rank test. Logistic regression analysis
was used to test for differences in complication rates between ciated with poorer survival and a more frequent occur-
families. rence of complications [9–11]. Although a wide range of
Results. Haplotype analysis revealed that each family had mutations have been reported within the PKD1 gene,
PKD1-linked disease with a unique disease-associated haplo-
they have been found in only a small proportion of fami-type. Interfamily differences were observed in overall survival
lies studied. The reasons for this low yield are the large(P 5 0.0004), renal survival (P 5 0.0001), hypertension preva-
lence (P 5 0.013), and hernia (P 5 0.048). Individuals with size of the gene and the presence of several duplications
hypertension had significantly worse overall (P 5 0.0085) and with high homology, involving approximately two thirds
renal (P 5 0.03) survival compared with those without hyper- of the gene at the 59 end [3, 12–20]. As a result, nottension. No statistically significant differences in the prevalence
enough data have yet become available to determineof hypertension and hernia were observed among controls.
whether the nature of the underlying mutation influencesConclusion. We conclude that phenotype differences exist
between PKD1 families, which, on the basis of having unique disease severity. In contrast, familial differences, corre-
disease-associated haplotypes, are likely to be associated with lating with different mutations in the same gene, have
a heterogeneous range of underlying PKD1 mutations. been observed in a number of other genetic diseases,
including cystic fibrosis, familial polyposis coli, hypertro-
phic obstructive cardiomyopathy, and Marfan syndrome
Autosomal dominant polycystic kidney disease
[21–24]. In view of the wide variety of PKD1 mutations
(ADPKD) is an important cause of chronic renal failure,
that have been identified to date, it is possible that there
with approximately 77% of patients deceased or with end-
is interfamily variability of PKD1 clinical expression.stage renal disease (ESRD) at the age of 70 years [1].
Until a larger proportion of mutations across all regions
of the PKD1 gene can be identified, evidence to assess
1 See Editorial, p. 344. whether the nature of the underlying PKD1 mutation
influences the disease phenotype is reliant on statisticalKey words: kidney, polycystic kidney disease, heredity, hypertension,
hernia, gene mutations. comparison of the phenotypes found in large PKD1 fami-
lies. To test the hypothesis that there are differences inReceived for publication August 17, 1998
clinical expression between PKD1 families, we evaluatedand in revised form February 3, 1999
Accepted for publication February 19, 1999 10 large PKD1-linked families from the same geographic
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METHODS Non-affected. Family members at 25 or 50% risk of
having inherited ADPKD who had been found to haveFamilies and clinical evaluation
a normal ultrasound scan over the age of 30 or who wereLarge ADPKD families with 12 or more members
at a less than 1% risk of having inherited the PKD1 geneknown to be affected were selected from the South Wales
according to linkage analysis were included as controls.ADPKD register. Within each family, information was
Survival data were recorded, as well as information aboutcollected from three categories of ADPKD-affected in-
the following: hypertension requiring treatment, macro-dividuals and also from at-risk family members who were
hematuria, urinary tract infection, urinary tract calculi,proven to be non-affected.
and hernia of the anterior abdominal wall.Previously diagnosed. The medical history and cur-
The ethical committees of Morriston Hospital inrent renal symptoms of previously diagnosed individuals
Swansea and the University Hospital of Wales in Cardiffwere recorded, including age at diagnosis, the factors
both approved this study, and DNA samples were takenleading to diagnosis, as well as information on the follow-
after informed consent was obtained from patients anding: hypertension requiring treatment, macrohematuria,
their family members.urinary tract infection, urinary tract calculi, and hernia
of the anterior abdominal wall. For macrohematuria, a DNA microsatellite analysis
history of passing urine with visible blood was regarded
Four families were already known to be linked to theas sufficient. Individuals were considered to have suf-
PKD1 gene, and the methods and results of the linkagefered from urinary tract infection if, at any stage in the
analysis have been reported elsewhere [26]. Using micro-past, they had been diagnosed or treated for cystitis,
satellite polymorphisms, the remaining six families werepyelonephritis, or cyst infection. A positive urine or
tested for evidence of linkage to the PKD1 locus. Weblood culture was not required for the diagnosis. For
used the CA repeat KG8 (intragenic marker at the 39urinary tract calculi, radiological evidence of stone for-
end of the gene) and the complex polymorphism SM6mation (ultrasound, plain x-rays, intravenous pyelo-
(proximal to the gene). Haplotype analysis was per-grams, CT scans) was required. Any history of hernia of
formed on all families to assess for the presence of possi-the anterior abdominal wall, that is, inguinal or umbilical
ble common founder mutations. The markers KG8, SM6,hernia, was sufficient for inclusion, regardless of the size
and SM7, all tightly linked to the PKD1 locus, were usedor treatment modality. The age at the onset of renal
to determine family haplotypes. Genomic DNA (30 ng)failure was recorded for those on renal replacement ther-
was polymerase chain reaction (PCR) amplified in a finalapy. When necessary, additional medical details were
volume of 12.5 ml containing, 1 3 Cetus buffer II (PEobtained from the attending doctor.
Applied Biosystems, Warrington, UK), 1.5 mmol/literNewly diagnosed. These were individuals with an af-
MgCl2, 200 mmol/liter of each dATP, dGTP, dCTP, andfected parent who was not previously known to have
dTTP (Pharmacia LKB, Piscataway, NJ, USA), 3 pmolADPKD and who was diagnosed during this study by
of each primer [one of primers was end labeled with 0.22ultrasound examination [25] or DNA-linkage tests. Like
mCi of g33PdATP, 1 3 kinase buffer 0.33 units kinasethe previously diagnosed group, their medical history
enzyme (Life Technologies, Ltd., Paisley, UK)] and onewas recorded, together with documentation of any exist-
unit of Amplitaq Gold (Applied Biosystems). Amplifi-ing renal symptoms. Physical examination included rest-
cation conditions were an initial denaturing step (12 mining supine and erect systolic and diastolic (phase V)
for 958C), followed by 29 cycles of 948C for 60 seconds,blood pressure measurements. The World Health Orga-
the primer specific annealing temperature (Ta) for 60nization criteria for hypertension were used, and individ-
seconds and 728C for 60 seconds. A final extension stepuals were considered to be hypertensive if the systolic
for 60 seconds at the Ta and for 10 minutes at 728C wasblood pressure was $160 mm Hg or the diastolic blood
performed. The Ta was 568C for KG8 and 608C for SM6pressure was $95 mm Hg. Abdominal ultrasound was
and 558C for SM7. Polymerase chain reaction (PCR)arranged, and the presence and number of renal and
products were run on a 6% denaturing polyacrylamidehepatic cysts were recorded.
gel (National Diagnostics, Atlanta, GA, USA). The gelDeceased affected. Information was collected on af-
was vacuum dried and autoradiographed for approxi-fected individuals who had died, including their dates of
mately 18 hours.birth and death, mode of and age of diagnosis, complica-
tions when known, particularly hypertension requiring
Linkagetreatment, and cause of death. The age at onset of end-
Linkage analyses were performed on the 10 familiesstage renal failure was taken to be the age at which long-
using CYRILLIC 2.0 (Cherwell Scientific Publishing,term replacement therapy for renal function became nec-
Ltd., Oxford, UK) and the MLINK program [27]. Familyessary or, in people who died of renal failure, the age
at death. LOD scores were included in the following weighting
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Table 1. Survival data of 10 South Wales PDK1 families
Median renal
Number of Number Median survival Number survival (to ESRD)
Family affected members deceased/ESRD (to ESRD/death) ESRD (95% CI)
1 37 25 47.6 (44.5–50.6) 20 48.4 (43.8–52.9)
2 13 8 49.0 (43.2–54.8) 7 55.0 (44.2–65.8)
3 12 7 48.0 (39.9–56.1) 2 61.3 (30.0–92.6)
4 16 8 49.9 (44.3–55.6) 5 54.5 (45.1–63.7)
5 13 8 49.3 (47.0–51.6) 6 50.0 (48.2–51.8)
6 15 9 52.5 (47.0–58.1) 6 55.1 (49.8–60.4)
7 12 8 45.3 (35.3–55.2) 7 45.3 (35.3–55.2)
8 17 11 47.9 (40.6–55.3) 6 49.5 (47.6–51.4)
9 26 10 48.0 (46.2–49.8) 5 57.0 (47.7–66.3)
10 14 4 75.3 (54.2–76.1) 1 75.3a
Total 175 98 49.0 (47.4–50.6) 25 47.6 (44.5–50.6)
a Unable to calculate CI because of lack of endpoints
Table 2. LOD scores (Z) and final probabilities of being linked toformula to estimate the likelihood of a family being
the PKD1 locus of 10 South Wales families
linked to the PKD1 locus.
Final probability
P(PKD1) 5 (aPKD1)(10LodPKD1)/[(aPKD1)(10LodPKD1) Family Z PKD1 linked
1 9.1 .0.9991 (aPKD2) 1 (1–aPKD1 –aPKD2)] 2 4.1 .0.999
3 1.4 0.992The prevalence estimates used for PKD1 (aPKD1), PKD2 4 1.5 0.994
(aPKD2), and 1-aPKD1 –aPKD2 were 0.84, 0.15, and 0.01, re- 5 3.3 .0.999
6 2.8 .0.999spectively.
7 3.8 .0.999
8 3.0 .0.999Statistical methods
9 8.2 .0.999
10 1.9 0.998The product-limit method of survival analysis was used
to determine survival probabilities. For overall survival,
the endpoint was defined as the age at death or onset
of ESRD. Affected individuals who were still alive and
PKD1 locus was more than 99% for all families (Table 2).not in ESRD were entered as censored data. For renal
Haplotype analysis revealed the presence of a uniquesurvival, the endpoint was defined as the age at onset of
disease-associated haplotype in each family. InterfamilyESRD. Individuals who died of causes other than uremia
differences were detected when comparing overall sur-and who had not reached ESRD during their lifetime
vival (log rank test, P 5 0.0004; Fig. 1). Family 7 hadwere included as censored data. Survival differences
the shortest survival, with a median age of 45.3 years,were analyzed by the log rank test. When investigating
and family 10 had the longest, with a median age of 75.3differences in frequencies of complications between the
years. Inspection of Figure 1 suggested that family 10groups of affected family members, logistic regression
may be an unusual outlier. In view of this, the familyanalysis was used to adjust for the effects of age and sex,
was removed from the group, and the analysis was re-and the same method was used to investigate differences
peated. The log rank test revealed the persistence of abetween the groups of nonaffected family members. The
significant difference of phenotype among the remaininganalyses were performed using the statistical package
nine PKD1 families (P 5 0.018). For renal survival (Fig-SPSS version 6.0.
ure 2), the difference between families was also highly
significant (P 5 0.0001). Again, the removal of family
RESULTS 10 did not result in the loss of a statistically significant
difference between the remaining families (P 5 0.011).Ten families, with a mean of 17.5 (12 to 37) affected
members, were identified (Table 1). The 175 ADPKD Analysis of the survival data of nonaffected family mem-
bers was hampered by the small number of individualsaffected members of these families comprised 83 men
and 92 women, of whom 98 (56%) had died or had who were proven to be nonaffected before their death,
and in five families, none of the controls had reached anreached ESRD. Information from 88 nonaffected indi-
viduals, 46 men and 42 women, was available for analysis. endpoint, therefore preventing the comparison of sur-
vival data.The linkage to the PKD1 locus on chromosome 16p13.3
was confirmed for all 10 families, with LOD scores rang- Although the prevalence of hypertension in affected
individuals increased with age (x2 5 28.7, P , 0.00001),ing from 1.4 to 9.1, indicating that the linkage to the
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Fig. 1. Overall survival for 10 South Wales
PKD1 families (endpoint defined as death or
end-stage renal disease).
Fig. 2. Renal survival for 10 South Wales
PKD1 families (endpoint defined as end-stage
renal disease).
there was no significant difference between affected P 5 0.032) and was higher in women, although this did
not reach statistical significance (x2 5 3.84, P 5 0.050).males and females (x2 5 0.14, P 5 0.71). Logistic regres-
sion analysis, correcting for age and sex, showed a sig- After correcting for age and sex, no significant difference
was observed between families. As expected, womennificant difference in the prevalence of hypertension oc-
curring in the 10 families (x2 5 20.82, P 5 0.013). experienced more urinary tract infections than men (x2 5
14.92, P 5 0.00011). After correcting for sex and age,Kaplan–Meier survival analysis, corrected for sex,
showed that individuals with hypertension, compared no significant difference between families was identified.
The prevalence of hernia increased with age (x2 5 4.14,with those without hypertension, had significantly worse
overall survival (P 5 0.0085), as well as renal survival P 5 0.042) and was higher in men, although this gender
difference did not reach statistical significance (x2 5 3.79,(P 5 0.03). The prevalence of macrohematuria was ob-
served to rise with increasing age (x2 5 9.43, P 5 0.0021). P 5 0.052). After correcting for age and sex, a significant
difference between families was identified (x2 5 17.04,After correcting for sex and age, the prevalence of mac-
rohematuria did not differ significantly between PKD1 P 5 0.048). Among the nonaffected control population,
the prevalence of hypertension increased with age (x2 5families. The prevalence of renal stones, demonstrated
by radiological imaging, increased with age (x2 5 4.62, 16.21, P , 0.0005), and no statistically significant differ-
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ence was detected between the prevalence in males and the description of a PKD1 kindred with an overlap con-
nective tissue syndrome, reminiscent of Marfan syn-females (x2 5 0.02, P 5 0.89). In contrast to the findings
among affected individuals, no statistically significant dif- drome, is of interest [35]. The observation of significant
variation in the prevalence of abdominal hernia amongferences in the prevalence of hypertension were found
between the 10 groups of nonaffected subjects (x2 5 the PKD1 families in this study could indicate that some
PKD1 mutations predispose to an increased risk of con-9.19, P . 0.4). The prevalence of abdominal wall hernia
increased with age in the control population (x2 5 14.97, nective tissue complications. Although this finding is con-
sistent with other reports of familial clustering of aorticP , 0.0005) and was higher in men than in women (x2 5
5.02, P 5 0.025). After correcting for age and sex, no dissection and intracranial aneurysms [36, 37], proof of
the hypothesis that the nature of the underlying PKD1statistically significant differences were found for the
prevalence of hernia among the nonaffected members mutation influences the risk of connective tissue compli-
cations will have to await the identification of specificof the different families (x2 5 9.96, P . 0.3).
mutations in families with unusual connective tissue fea-
tures.
DISCUSSION
Although no interfamily differences were observed in
These data demonstrate for the first time, to our the prevalence of urinary tract infection, macrohematu-
knowledge, that phenotype differences exist among ria, and renal calculi, it must be pointed out that limita-
PKD1 families. In addition to differences in overall sur- tions to the power of interfamily comparative studies
vival and renal survival, we detected marked familial such as this prevent detection of less obvious differences,
variation in the prevalence of disease-associated compli- even if they existed.
cations, which persisted after the correction for age and Only two previous studies have compared patterns of
sex. Among those complications, the prevalence of hy- clinical expression within and between ADPKD families
pertension varied the most between families. Significant [38, 39]. The study by Milutinovic et al demonstrated by
variation in the prevalence of hernia of the anterior ab- means of pair analysis that the phenotypic expression of
dominal wall was also observed. These differences in the ADPKD has considerable intrafamilial variation and
prevalence of hypertension and hernia were not detected that the intrafamilial and interfamilial patterns of pro-
between the groups of nonaffected family members, gression of disease did not differ significantly [38]. In the
strongly suggesting that the observed differences are study by Torra et al, interfamilial variability, based on
most likely related to the nature of the underlying PKD1 age of onset of ESRD, was observed to be higher than
mutation, although it remains possible that other genetic intrafamilial variability [39]. Neither study separated out
influences linked to the PKD1 locus could play a role in PKD1 from PKD2 or other genotypes. Setting aside
determining disease severity. these earlier reports and the study reported here, there
Hypertension occurs commonly in ADPKD and fre- are no other reports comparing survival data among
quently develops before renal function becomes im- PKD1 families.
paired [28, 29]. The pathogenesis of hypertension in Although a considerable number of mutations and
ADPKD is complex with cyst growth, renal handling polymorphisms have been identified in the PKD1 gene,
of sodium, activation of the renin-aldosterone system, as well as in the PKD2 gene, it is not known to what
elevated plasma volume, and increased atrial natriuretic extent the nature of the underlying mutation correlates
peptide and plasma endothelin levels all found to be with the human ADPKD phenotype. For PKD1, because
associated with hypertension in this disorder [30]. Previ- of the complexities of screening for mutations in the
ous reports, as well as the data reported here, reveal duplicated region, most mutations reported to date are
that hypertension is strongly associated with a poorer from the single copy region at the 39 end of the gene. The
survival, including renal survival [1, 31]. Aside from in- majority of these mutations are stop or frame shifting
creasing the rate of renal decline, it is likely that the high mutations, resulting in premature truncation of the
prevalence of hypertension contributes to cardiovascular PKD1 gene product. Another type of PKD1 mutation
disease, the most frequent cause of death in ADPKD involves large deletions, disrupting the PKD1 gene and
patients [32]. Our observation that the prevalence of the adjacent tuberous sclerosis type 2 gene (TSC2).
hypertension varied the most supports the view that hy- These contiguous gene deletions result in tuberous scle-
pertension is an important determinant of overall sur- rosis and severe, childhood onset, polycystic kidney dis-
vival, as well as of renal survival. ease [40, 41] and are currently the only clear evidence
Inguinal and umbilical hernia are well-known compli- of a genotype/phenotype correlation involving PKD1.
cations of ADPKD [33, 34], which, along with cardiac More recently, several different strategies have been ap-
valve defects and intracranial aneurysms, may be the plied to identifying mutations in the duplicated region
result of a thus far unidentified extracellular matrix func- of the PKD1 gene [17, 18]. However, the yield remains
low, and mutations have been characterized in only ation of one or both of the polycystins. In this context,
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